Shattuck Labs Announces Positive Data from the Preclinical GLP Toxicology Study of SL-325 at the 20th Congress of European Crohn's and Colitis Organization (ECCO) in Inflammatory Bowel Diseases 2025
Portfolio Pulse from
Shattuck Labs announced positive preclinical data for SL-325, a DR3 blocking antibody for inflammatory bowel disease, showing no toxicity in non-human primates. The data suggests extended dosing intervals, with an IND filing expected in Q3 2025.
February 20, 2025 | 2:15 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Shattuck Labs reported positive preclinical results for SL-325, a DR3 blocking antibody for IBD, with no toxicity observed in non-human primates. This suggests potential for extended dosing intervals and an IND filing is expected in Q3 2025.
The positive preclinical data for SL-325, showing no toxicity and potential for extended dosing intervals, is a significant milestone for Shattuck Labs. This progress towards an IND filing in Q3 2025 could enhance investor confidence and positively impact the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100